Biology
Molecular Basis of Familial Hypercholesterolemia
Quick fact
About 1 in 250 people worldwide has familial hypercholesterolemia, yet most remain undiagnosed. Without treatment, many experience heart attacks before age 50.
Why this is interesting
What if your blood had dangerously high cholesterol from birth—no matter how healthy you ate? That's the reality for people with familial hypercholesterolemia, a condition caused by specific gene mutations.
Read the full explanation
Understanding Molecular Basis of Familial Hypercholesterolemia
Think of LDL cholesterol as a delivery truck carrying cholesterol to cells. Normally, cells have 'dock' proteins (LDL receptors) on their surface that catch these trucks and pull them inside, clearing LDL from the blood. In familial hypercholesterolemia, this docking system is broken. Because of a gene mutation, either the dock is missing or defective, the truck doesn't fit properly, or the dock is destroyed too quickly. As a result, LDL remains in the blood, building up in artery walls and causing hardening of the arteries (atherosclerosis) after years of accumulation.
A deeper explanation
The liver is the main organ that removes LDL from circulation, using LDL receptors on its cell surfaces. These receptors bind to a protein on the LDL particle, called apoB-100, and then pull the whole complex inside the cell. This process—receptor-mediated endocytosis—is critical for maintaining cholesterol balance. Mutations in the LDLR gene are the most common cause of FH and can affect every step: they may prevent production of the receptor, stop its transport to the surface, impair LDL binding, or block internalization. A second cause is mutations in APOB, the gene encoding the LDL's binding protein, so that the LDL particle no longer fits the receptor. A third cause involves PCSK9, a protein that normally triggers degradation of LDL receptors. Certain gain-of-function mutations in PCSK9 cause excessive receptor destruction, leaving fewer docks available. Since FH is autosomal dominant, having one mutated copy of these genes is enough to strongly elevate LDL levels. Sometimes, people inherit two defective copies, causing an even more severe, childhood-onset form. Understanding these molecular defects is crucial because it explains why standard therapy may have varying success. For example, statins reduce cholesterol production and upregulate LDL receptors, but if a mutation prevents receptor formation, statins are less effective. This knowledge directly motivated the development of PCSK9 inhibitors—antibodies that block PCSK9 from destroying receptors, thereby preserving LDL receptors and enhancing clearance. These therapies exemplify how a molecular understanding of a genetic disorder leads to targeted interventions.